Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Immunic Q4 EPS $(0.48) Beats $(0.51) Estimate, Cash And Equivalents As Of December 31, 2023 Were $46.7M

Author: Benzinga Newsdesk | February 22, 2024 07:37am
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.51) by 5.88 percent. This is a 70.37 percent increase over losses of $(1.62) per share from the same period last year.

Posted In: IMUX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist